论文部分内容阅读
目的探讨妊娠期高血压病患者血管活性因子水平的变化,为探讨妊娠期高血压病患者血管活性因子水平变化的临床诊治提供借鉴。方法选取深圳市妇幼保健院2014年12月-2016年1月,临床收治的妊娠期高血压病患者88例为研究组,同时选取同期入院健康的妊娠期孕妇88例为对照组。针对两组研究对象的降钙素基因相关肽、神经肽Y、可溶性血管细胞黏附分子-1和吸可溶性细胞间黏附因子-1进行观察。结果对照组的降钙素基因相关肽(CGRP)水平显著高于治疗前的研究组,对照组的神经肽Y(NPY)和s VCAM-1均显著低于治疗前的研究组;研究组治疗后CGRP、NPY和可溶性血管细胞黏附分子-1(s VCAM-1)等指标较治疗前均得到显著改善,差异具有统计学意义(P<0.05)。结论高血压病可导致妊娠期孕妇血管活性因子水平发生改变,针对患者CGRP、NPY和s VCAM-1等指标的监测,可辅助患者高血压病的临床诊治。
Objective To investigate the changes of vasoactive factors in patients with hypertensive disorder complicating pregnancy and provide references for clinical diagnosis and treatment of the changes of vasoactive factors in patients with hypertensive disorder during pregnancy. Methods Shenzhen MCH hospital from December 2014 to January 2016, 88 patients with hypertensive disorder admitted to clinic were enrolled in the study, and 88 healthy pregnant women of the same period were selected as the control group. Calcitonin gene-related peptide, neuropeptide Y, soluble vascular cell adhesion molecule-1 and soluble intercellular adhesion molecule-1 were observed in two groups. Results The levels of calcitonin gene-related peptide (CGRP) in the control group were significantly higher than those in the pretreatment study group. Neuropeptide Y (NPY) and s VCAM-1 in the control group were significantly lower than those in the pretreatment study group. The treatment group After CGRP, NPY and soluble VCAM-1 were significantly improved compared with before treatment, the difference was statistically significant (P <0.05). Conclusion Hypertension can lead to changes in the levels of vasoactive factors in pregnant women during pregnancy. The monitoring of CGRP, NPY and sVCAM-1 in patients with hypertension can help patients with hypertension.